key: cord-0294923-uorz6n0w
authors: Ratcliff, J. D.; Al-Beidh, F.; Bibi, S.; Bonsall, D.; Costa Clemens, S. A.; Estcourt, L.; Evans, A.; Fish, M.; Folegatti, P. M.; Gordon, A. C.; Jay, C.; Jennings, A.; Laing, E.; Lambe, T.; Macintyre-Cockett, G.; Menon, D.; Mouncey, P. R.; Nguyen, D.; Pollard, A. J.; Ramasamy, M. N.; Roberts, D. J.; Rowan, K. M.; Rynne, J.; Shankar-Hari, M.; Williams, S.; Harvala, H.; Golubchik, T.; Simmonds, P.; AMPHEUS Project,; REMAP-CAP Immunoglobulin Domain UK Investigators,; Group, Oxford COVID-19 Vaccine Trial
title: Highly-Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe Polymerase Chain Reaction
date: 2021-11-02
journal: nan
DOI: 10.1101/2021.11.01.21265384
sha: 1a039ede74f8e0b6e9edbae80716ab4a4a8cc347
doc_id: 294923
cord_uid: uorz6n0w

Introduction: Tools to detect SARS-Coronavirus-2 variants of concern and track the ongoing evolution of the virus are necessary to support ongoing public health efforts and the design and evaluation of novel COVID-19 therapeutics and vaccines. Although next-generation sequencing (NGS) has been adopted as the gold standard method for discriminating SARS-CoV-2 lineages, alternative methods may be required when processing samples with low viral loads or low RNA quality. Methods: An allele-specific probe polymerase chain reaction (ASP-PCR) targeting lineage-specific single nucleotide polymorphisms (SNPs) was developed and used to screen 1,082 samples from two clinical trials in the United Kingdom and Brazil. Probit regression models were developed to compare ASP-PCR performance against 1,771 NGS results for the same cohorts. Results: Individual SNPs were shown to readily identify specific variants of concern. ASP-PCR was shown to discriminate SARS-CoV-2 lineages with a higher likelihood than NGS over a wide range of viral loads. Comparative advantage for ASP-PCR over NGS was most pronounced in samples with Ct values between 26-30 and in samples that showed evidence of degradation. Results for samples screened by ASP-PCR and NGS showed 99% concordant results. Discussion: ASP-PCR is well-suited to augment but not replace NGS. The method can differentiate SARS-COV-2 lineages with high accuracy and would be best deployed to screen samples with lower viral loads or that may suffer from degradation. Future work should investigate further destabilization from primer:target base mismatch through altered oligonucleotide chemistry or chemical additives.

The ongoing evolution of SARS-CoV-2 leading to emergence of variants of concern 2 (VoC) and variants of interest (VoI) has highlighted the need for broadly accessible 3 methods for detecting and tracking mutations in the SARS-CoV-2 genome. Next-4 generation sequencing (NGS) with a collection of different methods and protocols has 5 been largely adopted as the gold standard approach for detecting SARS-CoV- 2 6 variants. Several targeted and untargeted whole-genome NGS methods have been 7 deployed for sequencing SARS-CoV-2, including the tiling amplicon-based ARTIC 8 protocol and targeted enrichment RNA-seq-based veSeq protocol. 1,2 9

10 Tools to identify the emergence of novel SARS-CoV-2 variants and track their spatial 11 spread are necessary to support public health interventions. Single-nucleotide 12 polymorphisms (SNPs) such as S:D614G may be associated with increased 13 transmissibility. 3 constellations of mutations that, to varying degrees, appear to impact transmissibility, 16 severity, and evasion of vaccine-derived immune responses. 4 Rapid identification of 17 novel lineages through NGS is necessary for accurate characterization and risk 18 assessment. However, recovering whole-genome sequences for samples with low viral 19 load is challenging and RNA quality must be high, conditions that may not be met in 20 samples taken from patients in the later phases of infection where viral loads may be 21 low or in settings where optimal sample handling and storage is not readily available. 5,6 22 In particular, high levels of RNA degradation during storage or transport of primary 23 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint material or RNA extracts can severely impact the effectiveness of amplicon-based 24 protocols such as ARTIC, the most popular SARS-CoV-2 sequencing technique, 1 25 because of its dependence on the generation of 400bp amplicons in its pre-amplification 26 step. 27 28 Herein, we describe the development and application of a polymerase chain reaction 29 (PCR)-based, high-throughput method for SARS-CoV-2 lineage designation -allele-30 specific probe (ASP)-PCR -and describe its application in two patient cohorts. ASP-31 PCR leverages differential binding affinities of two fluorescently-labelled probes differing 32 in the base overlapping a SNP site to designate SNPs at lineage informative locations in 33 the SARS-CoV-2 genome. The method uses similar amplicon length (120-200 bp) and 34 technology as real-time quantitative PCR (RT-qPCR), it is therefore more robust to 35 degraded RNA than ARTIC and accessible to most microbiology laboratories. Here, 36 ASP-PCR was applied to detect three SNPs in the SARS-CoV-2 genome, each highly 37 specific and selective for VoCs and VoIs relevant to the respective trials. recruitment. 9 Indeed, our previously published data indicated >50% of trial infections 46 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint occurring after the second week of December were due to Alpha, reaching >80% of new 47 infections by the end of trial recruitment. 10 To detect and differentiate those infections 48 caused by Alpha, the spike mutation S:D1118H was targeted by ASP-PCR. The 49 COV003 trial is a phase III trial of the ChAdOx1 nCoV-19 vaccine in Brazil that 50 overlapped the emergence of both the Gamma (pangolin: P.1) and P.2 variants in the 51 country. 11, 12 For these, ASP-PCR assays were designed targeting the spike mutation 52 S:K417T for Gamma and ORF1a:L3468V for P.2. 53

In both trials, we compared the ability of ASP-PCR and the veSeq NGS method to 55 perform lineage designation. While not as widely used as the ARTIC protocol, veSeq 56 involves bait capture rather than amplicons, and as such is more resistant to RNA 57 fragmentation and degradation, which was necessary given the quality of RNA in the 58 COV003 trial, and allows for robust, quantitative assessment of viral minor populations. 59

Application of probit regression models for each technique derived from the two patient 60 cohorts to a simulated viral load dataset clearly demonstrate the increased sensitivity of 61 ASP-PCR over NGS for specific allele genotyping and lineage discrimination across a 62 wide range of viral loads in both cohorts. 63 64 RESULTS 65 66 SNP sensitivity and specificity. To assess the suitability of different SNP targets for 67 lineage specification in the ASP-PCR platform, global sequencing data published as 68 part of the GISAID repository was utilized, leveraging the collation performed by 69 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint Outbreak.info (https://outbreak.info). 13, 14 The sensitivity, specificity, positive predictive 70 value (PPV), and negative predictive value (NPV) for various lineage-defining SNPs 71 within the countries where the samples were collected was calculated (Table 1) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. total samples quantified in the trial. In COV003, a >25% greater likelihood of producing 106 a lineage designation over NGS -Pangolin was seen for the viral load range of 8.53 * 107 10 1 -6.90 * 10 6 IU/mL and over NGS -SNP for viral loads in the range of 1.56 * 10 1 -108 5.77 * 10 7 IU/mL (Figure 1b) , a wider range than for REMAP-CAP but peaking at a 109 lower maximum percentage difference. For COV003, for which the distribution of viral 110 loads was more skewed to higher values, these ranges capture 39.8% and 59.6%, 111 respectively, of the viral loads of the 653 total samples quantified by RT-qPCR. At 112 functionally all viral loads in both trials, ASP-PCR was superior to NGS for making a 113 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint lineage designation with NGS -SNP/Pangolin only marginally outperforming ASP-PCR 114 at extreme viral loads not seen in samples quantified in the trials. 115

Concerns regarding the quality of RNA from several recruitment sites in the COV003 117 trial motivated by short average read lengths prompted investigation of the utility of 118 ASP-PCR for degraded samples. Degraded samples were defined as those that 119 returned a viral load estimate >10 6 IU/mL (Ct value ~26 or less in CDC N1 RT-qPCR 120 assay) but fewer than 20,000 bases with a read depth of at least two reads. Subsetting is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint However, this discrepancy was likely due to miscalls by Pangolin, as 17/18 of these 137 discordant samples were typed as Gamma or P.2 by phylogenetic reconstruction 138 (supplementary methods), leading to a more accurate assessment of ASP-PCR and 139 NGS concordance for COV003 of 99% (121/122). 140

Validation data for ASP-PCR has been presented elsewhere. 10 Ct or viral load data (Table 3) . 17 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint

CoV-2 SNPs as they arise. In our experience, SNP targets should fulfill most or all of 252 the following criteria to ease design and optimization: 253

• Follow best practices for primer/probe design and amplicon length as specified CoV-2 microbiological test. A full trial protocol and efficacy results are available 296 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint elsewhere. 7, 8 Oropharyngeal or nasopharyngeal swabs were taken prior to 297 randomization, transported to a central academic hospital and frozen at -80°C, shipped 298 on dry ice to a central testing laboratory, and processed as described below. 299 300 COV003 is a participant-blinded, randomized, controlled phase 3 multi-site trial that 301 began in Brazil on June 23, 2020 assessing the efficacy of the ChAdOx1 nCoV-19 302 vaccine against symptomatic SARS-CoV-2 infection. Efficacy, safety data, the full study 303 protocol, and exploratory analysis of lineage-specific efficacy are available 304 elsewhere. 16, 26, 27 Volunteers recruited for the trial were 18 years or older and at high risk 305 of exposure (e.g., healthcare workers). Volunteers who developed primary COVID-19 306

symptoms were asked to contact their study site. Nasopharyngeal swab samples that 307 were separately confirmed SARS-CoV-2 positive using commercial NAAT assays at 308 local laboratories were shipped to a central testing laboratory and processed as 309 Real-Time PCR system using the genotyping program. SNPs were designated based 342 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint on their clustering with discrimination controls. Serially diluted cDNA aliquots of 343 sequence-confirmed samples were used as discrimination controls; ultrapure water 344 served as negative controls. Samples that failed to achieve a change in signal in either 345 probe greater than those of the no template controls or lacked evidence of amplification 346 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint Degraded samples were defined as those with high viral loads (>=10 6 IU/mL) but poor 366 genome coverages (<=20,000 bases with read depth of at least two reads). 367 Data analysis. Probit regression models were generated using base function 'glm' in R 369 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint P a g e 8 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint P a g e 1 1

Panel A) Probit regression of likelihood of lineage designation success for ASP-PCR, NGS -SNP, and NGS -Pangolin derived from COV003 samples with 95% confidence intervals. B) Percentage difference between probit regression typing success rates for ASP-PCR vs NGS -SNP or NGS -Pangolin. C-E) Individual method performance on COV003 samples. Numbers above indicate total samples in one log data bins.

1 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint P a g e 1 2

Panel A) Probit regression of likelihood of lineage designation success for ASP-PCR, NGS -SNP, and NGS -Pangolin derived from degraded COV003 samples with 95% confidence intervals. NGS -SNP failed to type any samples with low genome coverage. B) Probit regression of likelihood of lineage designation success for ASP-PCR, NGS -SNP, and NGS -Pangolin derived from nondegraded COV003 samples with 95% confidence intervals. For A) and B), black box indicates viral loads >10 6 IU/mL. C) Genome coverage of COV003 samples plotted vs sample viral load. Samples with <= 20,000 bases with >= 2 reads and viral load > 10 6 IU/mL were defined as degraded (red 2 e. d . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint P a g e 1 3

box). D-F) Individual method performance on COV003 degraded and nondegraded samples. Numbers above indicate total samples in one log data bins.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint P a g e 1 4 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint P a g e 1 5

Percentage of total samples successfully typed using approach described in materials and methods. P values from Fisher's Exact Test. Lineage designation (e.g., WT or Alpha/B.1.1.7) were concordant for all samples for all methods. 5 ls or . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted November 2, 2021. ; https://doi.org/10.1101/2021.11.01.21265384 doi: medRxiv preprint

Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health

SARS-CoV-2 within-host diversity and transmission

Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus

The biological and clinical significance of emerging SARS-CoV-2 variants

Next generation sequencing of SARS-CoV-2 genomes: challenges, applications and opportunities

Multiple approaches for massively parallel sequencing of SARS-CoV-2 genomes directly from clinical samples

The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design

Writing Committee for the REMAP-CAP Investigators. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial

Investigation of novel SARS-CoV-2 variant: Variant of Concern

Virological and serological characterization of critically ill patients with COVID-19 in the UK: Interactions of viral load, antibody status and B.1.1.7 variant infection

Genomic Characterization of a Novel SARS-CoV-2 Lineage from Rio de Janeiro, Brazil

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Global initiative on sharing all influenza data -from vision to reality

Assignment of epidemiological lineages in an emerging pandemic using the pangolin tool

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

SARS-CoV-2 PCR cycle threshold at hospital admission associated with patient mortality

Correlation of Population SARS-CoV-2 Cycle Threshold Values to Local Disease Dynamics: Exploratory Observational Study

The views expressed in this publication are those of the authors and not necessarily those of any funding bodies. We thank all volunteers who supported both studies